Q-omics provides the consensus-scored MT1E profile across patient tissues and cancer cell-line models. MT1E expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, MT1E is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, MT1E protein abundance shows 14,468 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, KICH, and LSCC as cancer lineages where MT1E shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MT1E — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MT1E survival associations across molecular data types. MT1E RNA expression shows survival associations in the most cancer types (25), followed by mutation status (1) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MT1E RNA expression–survival associations across cancer types. High MT1E expression shows unfavorable associations in HNSC, PAAD, UVM and LGG, but favorable associations in KIRP and ESCA. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify HNSC as the clearest survival context for MT1E RNA expression.
This table summarizes MT1E tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MT1E. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MT1E shows lower tumor expression in KICH, COAD, THCA, KIRC, LIHC and KIRP. The KICH box plot shows higher MT1E RNA expression in normal versus tumor tissue (log2 FC = −4.897, t-test p < 0.001).
This table shows molecular features associated with MT1E in patient tissues and cancer cell lines. In patient samples, MT1E shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, MT1E RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BONE.
